Clinical TrialJun 2, 2026, 07:01 AM
BeyondSpring Plinabulin Phase 2 NSCLC data shows 7.0-month PFS, 58% 24-month OS
AI Summary
BeyondSpring Inc. announced updated positive efficacy and safety data from its investigator-initiated Phase 2 303 Study of pembrolizumab plus Plinabulin and docetaxel for metastatic non-small cell lung cancer (NSCLC) patients with acquired resistance to immune checkpoint inhibitors. The data, presented at ASCO 2026, showed a median Progression-Free Survival (PFS) of 7.0 months and a 24-month Overall Survival (OS) rate of 58.0%. The combination demonstrated durable survival benefit, good tolerability, and immune activation, suggesting Plinabulin's potential to address unmet needs in this patient population.
Key Highlights
- Median Progression-Free Survival (PFS) was 7.0 months, comparing favorably to historical docetaxel data (3.7-3.9 months).
- Median Duration of Response (DoR) was 9.3 months, indicating a durable response.
- Disease Control Rate (DCR) was 79.5%, showing clinical benefit in most patients.
- Confirmed Objective Response Rate (ORR) was 18.2%, favorable against historical 5-12% for docetaxel.
- 12-Month Overall Survival (OS) Rate was 78.1%, and 24-Month OS Rate was 58.0%, with median OS not reached.
- 53.2% of patients experienced grade 3 or higher treatment-related adverse events, with manageable safety profile.
Price Impact
More from BYSI